Endonovo Therapeutics ENDV Stock
Endonovo Therapeutics Price Chart
Endonovo Therapeutics ENDV Financial and Trading Overview
| Endonovo Therapeutics stock price | 0.0001 USD |
| Previous Close | 0.0001 USD |
| Open | 0.0001 USD |
| Bid | 0.0001 USD x 0 |
| Ask | 0.0001 USD x 22990398200 |
| Day's Range | 0.0001 - 0.0001 USD |
| 52 Week Range | 5.0E-5 - 0.0003 USD |
| Volume | 500K USD |
| Avg. Volume | 751.37K USD |
| Market Cap | 180.76K USD |
| Beta (5Y Monthly) | -8.448 |
| PE Ratio (TTM) | |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ENDV Valuation Measures
| Enterprise Value | N/A |
| Trailing P/E | |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.706839 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
Endonovo Therapeutics Stock Price History
| Beta (5Y Monthly) | -8.448 |
| 52-Week Change | 0% |
| S&P500 52-Week Change | 27.29% |
| 52 Week High | 0.0003 USD |
| 52 Week Low | 5.0E-5 USD |
| 50-Day Moving Average | 9.0E-5 USD |
| 200-Day Moving Average | 9.91E-5 USD |
ENDV Share Statistics
| Avg. Volume (3 month) | 751.37K USD |
| Avg. Daily Volume (10-Days) | 497.19K USD |
| Shares Outstanding | 1.81B |
| Float | 255.51M |
| Short Ratio | N/A |
| % Held by Insiders | 0% |
| % Held by Institutions | 0% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:1000 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | September 30, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -31105.065% |
| Gross Margin | 96.21% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -144.26% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 255.72K USD |
| Revenue Per Share (ttm) | 0.001 USD |
| Quarterly Revenue Growth (yoy) | -86.099% |
| Gross Profit (ttm) | 246.03K USD |
| EBITDA | -1969534 USD |
| Net Income Avi to Common (ttm) | -4404143 USD |
| Diluted EPS (ttm) | 0 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | N/A |
| Total Cash Per Share (mrq) | N/A |
| Total Debt (mrq) | 7.06M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.001 |
| Book Value Per Share (mrq) | -0.072 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -629904 USD |
| Levered Free Cash Flow (ttm) | 2.15M USD |
Profile of Endonovo Therapeutics
| Country | United States |
| State | CA |
| City | Woodland Hills |
| Address | 6320 Canoga Avenue |
| ZIP | 91367 |
| Phone | 800 489 4774 |
| Website | https://www.endonovo.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Endonovo Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and distribution of non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardio chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular, and peripheral artery disease (PAD) and ischemic stroke. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.
Q&A For Endonovo Therapeutics Stock
What is a current ENDV stock price?
Endonovo Therapeutics ENDV stock price today per share is 0.0001 USD.
How to purchase Endonovo Therapeutics stock?
You can buy ENDV shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Endonovo Therapeutics?
The stock symbol or ticker of Endonovo Therapeutics is ENDV.
Which industry does the Endonovo Therapeutics company belong to?
The Endonovo Therapeutics industry is Biotechnology.
How many shares does Endonovo Therapeutics have in circulation?
The max supply of Endonovo Therapeutics shares is 1.81B.
What is Endonovo Therapeutics Price to Earnings Ratio (PE Ratio)?
Endonovo Therapeutics PE Ratio is now.
What was Endonovo Therapeutics earnings per share over the trailing 12 months (TTM)?
Endonovo Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the Endonovo Therapeutics company belong to?
The Endonovo Therapeutics sector is Healthcare.